Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01241305
Other study ID # VCRC5510
Secondary ID U54AR057319-06
Status Recruiting
Phase
First received
Last updated
Start date October 2010
Est. completion date August 2027

Study information

Verified date June 2024
Source University of Pennsylvania
Contact Carol McAlear, MA
Email cmcalear@upenn.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to identify genes that increase the risk of developing vasculitis, a group of severe diseases that feature inflammation of blood vessels. Results of these studies will provide vasculitis researchers with insight into the causes of these diseases and generate new ideas for diagnostic tests and therapies, and will be of great interest to the larger communities of researchers investigating vasculitis and other autoimmune, inflammatory, and vascular diseases.


Description:

The systemic vasculitides comprise several inflammatory diseases of blood vessels, usually arteries, which may cause systemic, multi-organ disease that can result in substantial morbidity and increased mortality. Each type of vasculitis is a rare ("orphan") disease. However, taken together, vasculitis affects tens of thousands of Americans and is responsible for substantial morbidity and mortality and almost one billion dollars per year in hospital care alone. While the vasculitides share the trait of vascular inflammation, the unique disease phenotypes, clinical courses, differences in prognoses, and responses to therapy suggest that important differences exist in pathogenesis. The Vasculitis Clinical Research Consortium (VCRC) currently focuses on 6 specific types of vasculitis that were selected to represent a balance between unmet medical and scientific needs, prevalence in North America, feasibility of study, and an interest in studying a spectrum of small, medium, and large vessel vasculitides. The great majority of published studies on the genetics of vasculitis have used modest-sized cohorts that are only suitable for investigation of a few candidate genes at a time, or to detect large effect sizes, so that replicated findings are highly skewed to the HLA region. Larger and more ambitious genetic studies in vasculitis are expected to generate numerous hypotheses for translational research in gene expression, biochemistry, and molecular pathology. A one-time collection of clinical data and DNA would substantially increase the sample sizes for genetic association studies in all six vasculitides studied in the VCRC. Many patients are seen at participating VCRC centers but do not enroll in the Longitudinal Studies. These patients often are interested in participating in research studies but cannot return frequently for visits, usually due to distance from the VCRC centers. This approach would be particularly useful for the rarer forms of vasculitis under study (Takayasu's Arteritis (TAK), Polyarteritis Nodosa (PAN), eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) and also for Giant Cell Arteritis (GCA), since elderly patients have been particularly likely to decline participation in the Longitudinal Studies due to travel constraints.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date August 2027
Est. primary completion date August 2027
Accepts healthy volunteers No
Gender All
Age group 7 Years and older
Eligibility Inclusion Criteria: 1. Diagnostic criteria for Giant Cell Arteritis Age at disease onset >50 years (required) 1. New onset or new type of localized pain in the head 2. Temporal artery abnormality (i.e. temporal artery tenderness to palpation or decreased pulsation, unrelated to arteriosclerosis of cervical arteries) 3. ESR of >40mm in the first hour by the Westergren method 4. Abnormal artery biopsy (i.e. temporal artery biopsy showing vasculitis characterized by a predominance of mononuclear cell infiltration or granulomatous inflammation, usually with multinucleated giant cells) 5. Large Vessel Vasculitis (LVV) by angiogram or biopsy not explained by something else Inclusion Criteria: 2. Diagnostic criteria for Takayasu's Arteritis 1. Age at disease onset <50 years 2. Claudication of extremities 3. Decreased brachial artery pulse (one or both arteries) 4. Blood pressure difference of >10mm Hg between the arms 5. Bruit over subclavian arteries or aorta 6. Arteriogram abnormalities compatible with TAK (includes conventional dye angiography or MR angiography or CT angiography) Inclusion Criteria: 3. Diagnostic criteria for Polyarteritis Nodosa Major criteria (not explained by other causes) felt by investigator to be due to vasculitis 1. Arteriographic abnormality 2. Presence of granulocyte or mixed leukocyte infiltrate in an arterial wall on biopsy 3. Mononeuropathy or polyneuropathy Minor criteria (not explained by other causes) felt by investigator to be due to vasculitis 1. Weight loss > 4 kg 2. Livedo reticularis, cutaneous ulcerations, or skin nodules 3. Testicular pain or tenderness 4. Myalgias 5. Diastolic blood pressure > 90 mm Hg 6. Elevated BUN or serum creatinine levels 7. Ischemic abdominal pain Isolated cutaneous Polyarteritis Nodosa 1. Biopsy-proven cutaneous PAN Inclusion Criteria: 4. Diagnostic criteria for Granulomatosis with Polyangiitis (Wegener's) (GPA) and Microscopic Polyangitis (MPA) - Diagnosis of GPA or MPA. Widely accepted diagnostic criteria, as opposed to classification criteria or definitions, have not been developed for GPA & MPA. - For diagnosis of GPA meets at least 2 of the following 5 modified ACR criteria: 1. Nasal or oral inflammation with oral ulcers or nasal discharge with pus or blood 2. Abnormal chest radiograph with nodules, fixed infiltrates, or cavities 3. Urinary sediment with microhematuria or red cell casts 4. Granulomatous inflammation within the wall of an artery or in the perivascular area on biopsy 5. Antineutrophil cytoplasmic antibody (ANCA) positive by enzyme immunoassay for either PR3- or MPO-ANCA - For diagnosis of MPA, meets the Chapel Hill Consensus Conference Definition for MPA: 1. Necrotizing vasculitis, with few or no immune deposits, that affects small vessels (i.e., capillaries, venules, arterioles) 2. Necrotizing arteritis involving small- and medium-sized arteries may be present 3. Necrotizing glomerulonephritis is very common 4. Pulmonary capillaritis often occurs Inclusion Criteria: 5. Diagnostic criteria for Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss) 1. Asthma 2. Peak peripheral blood eosinophilia of >10% of total WBC 3. Peripheral neuropathy attributable to vasculitis 4. Transient pulmonary infiltrates on chest imaging studies 5. Paranasal sinus abnormalities or nasal polyposis 6. Eosinophilic inflammation on tissue biopsy If patients have 4 of the above 6 criteria but lack clearcut documentation of small vessel vasculitis, they are also eligible for enrollment. General Exclusion Criteria: - Inability to give informed consent and to sign the consent form - Enrolled in VCRC protocols 5502, 5503, 5504, 5505, 5506, 5522, or 5523 - Unwilling to provide blood for DNA collection

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Canada St. Joseph's Healthcare Hamilton Ontario
Canada Mount Sinai Hospital Toronto Ontario
Turkey Istanbul University Istanbul Fatih
United States University of Michigan Ann Arbor Michigan
United States Northwestern University Chicago Illinois
United States Cleveland Clinic Cleveland Ohio
United States University of Kansas Medical Center Kansas City Kansas
United States Cedars-Sinai Medical Center Los Angeles California
United States Hospital for Special Surgery New York New York
United States University of Pennsylvania Philadelphia Pennsylvania
United States University of Pittsburgh Pittsburgh Pennsylvania
United States Mayo Clinic Rochester Minnesota
United States University of Utah Salt Lake City Utah
United States University of California, San Francisco San Francisco California

Sponsors (4)

Lead Sponsor Collaborator
University of Pennsylvania National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Office of Rare Diseases (ORD), Rare Diseases Clinical Research Network

Countries where clinical trial is conducted

United States,  Canada,  Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of clinical data and linked DNA specimens. 1 year.
See also
  Status Clinical Trial Phase
Completed NCT03812302 - Use of Gallium-68 HA-DOTATATE PET/CT in Giant Cell Arteritis (GCA) Phase 2
Recruiting NCT02257866 - Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Recruiting NCT04888221 - Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement Phase 3
Recruiting NCT05380453 - Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission Phase 3
Recruiting NCT02333708 - Study of Circulating Microparticles in Giant Cell Arteritis
Completed NCT01450137 - Tocilizumab for Patients With Giant Cell Arteritis Phase 2
Completed NCT03827018 - KPL-301 for Subjects With Giant Cell Arteritis Phase 2
Active, not recruiting NCT04519580 - Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
Recruiting NCT04239196 - Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA Phase 2
Recruiting NCT06460142 - Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic
Completed NCT03202368 - An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA) Phase 3
Not yet recruiting NCT02523625 - Giant Cell Arteritis: Improving Use of Ultrasound Evaluation N/A
Completed NCT03285945 - FDG Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment N/A
Completed NCT02190916 - Vasculitis Illness Perception (VIP) Study N/A
Terminated NCT02531633 - Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis Phase 3
Completed NCT03765424 - Evaluation of Ultrasound and PET/CT in the Diagnosis and Monitoring of Giant Cell Arteritis
Completed NCT03409913 - Diagnostic Accuracy of FDG PET/CT of Cranial Arteries in GCA N/A
Completed NCT01910038 - Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study. Phase 2
Not yet recruiting NCT04012905 - Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering Phase 3
Recruiting NCT06004154 - Post-therapeutic Imaging Evaluation of Patients With Horton's Disease (Giant Cell Arteritis) (EvHortim)